Overview

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

Status:
Completed
Trial end date:
2019-09-29
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to investigate the safety, tolerability and pharmacokinetics (PK) of KPG-818 in healthy male and female participants and the effect of food on the PK of KPG-818. The study will assist in identifying appropriate, well tolerated doses that can be administered in subsequent studies in healthy participants and participants with systemic lupus erythematosus (SLE).
Phase:
Phase 1
Details
Lead Sponsor:
Kangpu Biopharmaceuticals, Ltd.